Targeting miR-506 in leiomyosarcoma therapy: simultaneous suppression of metastatic potential and potentiation of pirarubicin efficacy

Ting Li, Ruwei Xing, Feng Li, Jilong Yang

Open source

DOI: 10.21037/tcr-2026-1559
Published: 2026-10
Container: Translational Cancer Research
Publisher: AME Publishing Company
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21037/tcr-2026-1559,
  title = {Targeting miR-506 in leiomyosarcoma therapy: simultaneous suppression of metastatic potential and potentiation of pirarubicin efficacy},
  author = {Ting Li and Ruwei Xing and Feng Li and Jilong Yang},
  year = {2026},
  journal = {Translational Cancer Research},
  doi = {10.21037/tcr-2026-1559},
  url = {https://doi.org/10.21037/tcr-2026-1559}
}

RIS

TY  - JOUR
TI  - Targeting miR-506 in leiomyosarcoma therapy: simultaneous suppression of metastatic potential and potentiation of pirarubicin efficacy
AU  - Ting Li
AU  - Ruwei Xing
AU  - Feng Li
AU  - Jilong Yang
PY  - 2026
JO  - Translational Cancer Research
DO  - 10.21037/tcr-2026-1559
UR  - https://doi.org/10.21037/tcr-2026-1559
ER  -

APA

Li, T., Xing, R., Li, F., & Yang, J. (2026). Targeting miR-506 in leiomyosarcoma therapy: simultaneous suppression of metastatic potential and potentiation of pirarubicin efficacy. Translational Cancer Research. https://doi.org/10.21037/tcr-2026-1559

Source records

crossref · retrieved 2026-11-09T21:28:12.373Z